Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.

Currency in USD	2025
Operating Income	-381.68 Million
Income Before Tax	-379.6 Million
Income Tax Expense	1.79 Million
Net Income	-381.39 Million
Eps	-2.38
Epsdiluted	-2.38
Weighted Average Shs Out	160.01 Million
Weighted Average Shs Out Dil	160.01 Million
Research And Development Expenses	915.62 Million
Selling General And Administrative Expenses	393.87 Million
Depreciation And Amortization	22.69 Million
Interest Expense	17.26 Million
Interest Income	N/A
Net Interest Income	-90.58 Million
Premiums Earned	N/A
Policyholder Benefits	N/A
Gross Profit	927.80 Million
Ebitda	-359.02 Million
Source	edgar
Ebit	-295.32 Million

Ionis Pharmaceuticals, Inc. Annual Reports (10-K)